论文部分内容阅读
目的:探讨趋化因子配体18在人脑胶质瘤中表达情况及与患者预后相关性,分析其作为胶质瘤预后判断指标的可能性。方法:本文采用实时荧光定量PCR和Western Blotting方法检测CCL18在正常人脑组织及不同级别胶质瘤中的表达情况,并利用生存曲线对患者的生存预后进行分析。结果:CCL18在人胶质瘤组织中均高表达,且在高级别较低级别胶质瘤组织中表达更高,差异具有统计学意义(P<0.05),在低级别胶质瘤中相对于正常脑组织表达增加,差异具有统计学意义(P<0.05)。CCL18表达量越高,胶质瘤患者中位生存期越短(P<0.05)。结论:CCL18是神经胶质瘤恶性程度的重要标志,且可作为判断胶质瘤患者预后的指标。
OBJECTIVE: To investigate the expression of chemokine ligand 18 in human glioma and its relationship with the prognosis of patients, and to analyze its potential as a prognostic indicator of glioma. Methods: Real-time fluorescent quantitative PCR and Western Blotting were used to detect the expression of CCL18 in normal human brain tissues and gliomas at various stages. Survival curves were used to analyze the prognosis of patients. Results: CCL18 was highly expressed in human glioma tissues and higher in lower-grade gliomas, with a statistically significant difference (P <0.05). In low-grade gliomas, Normal brain tissue increased, the difference was statistically significant (P <0.05). The higher the CCL18 expression, the shorter the median survival of patients with glioma (P <0.05). Conclusion: CCL18 is an important marker of glioma malignancy, and can be used as an indicator to judge the prognosis of glioma patients.